Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus IMIPRAMINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus IMIPRAMINE PAMOATE.
AVENTYL HYDROCHLORIDE vs IMIPRAMINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline hydrochloride, the active ingredient in Aventyl Hydrochloride, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has antihistaminic, anticholinergic, and sedative properties.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum dose 150 mg/day.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life is approximately 19–24 hours; may be prolonged in elderly and patients with hepatic impairment.
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Primarily renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal excretion accounts for ~30%.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant